

# Vinicius G Maltarollo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11739278/publications.pdf>

Version: 2024-02-01

26  
papers

466  
citations

687363

13  
h-index

713466

21  
g-index

26  
all docs

26  
docs citations

26  
times ranked

597  
citing authors

#	ARTICLE	IF	CITATIONS
1	Recent Advances in the Prediction of Pharmacokinetics Properties in Drug Design Studies: A Review. <i>ChemMedChem</i> , 2022, 17, .	3.2	44
2	Synthesis of arylfuran derivatives as potential antibacterial agents. <i>Medicinal Chemistry Research</i> , 2021, 30, 1074-1086.	2.4	9
3	Knowing and combating the enemy: a brief review on SARS-CoV-2 and computational approaches applied to the discovery of drug candidates. <i>Bioscience Reports</i> , 2021, 41, .	2.4	16
4	Structure-Based Virtual Screening, Molecular Dynamics and Binding Free Energy Calculations of Hit Candidates as ALK-5 Inhibitors. <i>Molecules</i> , 2020, 25, 264.	3.8	7
5	Advances and Perspectives in Applying Deep Learning for Drug Design and Discovery. <i>Frontiers in Robotics and AI</i> , 2019, 6, 108.	3.2	60
6	Antibacterial activity of synthetic 1,3-bis(aryloxy)propan-2-amines against Gram-positive bacteria. <i>MicrobiologyOpen</i> , 2019, 8, e814.	3.0	16
7	GQ-11: A new PPAR agonist improves obesity-induced metabolic alterations in LDLr <sup>-/-</sup> mice. <i>International Journal of Obesity</i> , 2018, 42, 1062-1072.	3.4	15
8	On the relationship of anthranilic derivatives structure and the FXR (Farnesoid X receptor) agonist activity. <i>Journal of Biomolecular Structure and Dynamics</i> , 2018, 36, 4378-4391.	3.5	5
9	Transfer and Multi-task Learning in QSAR Modeling: Advances and Challenges. <i>Frontiers in Pharmacology</i> , 2018, 9, 74.	3.5	87
10	Quantitative structure-activity relationships (HQSAR, CoMFA, and CoMSIA) studies for COX-2 selective inhibitors. <i>Journal of Biomolecular Structure and Dynamics</i> , 2017, 35, 1436-1445.	3.5	17
11	Application of bioisosterism in design of the semicarbazone derivatives as cruzain inhibitors: a theoretical and experimental study. <i>Journal of Biomolecular Structure and Dynamics</i> , 2017, 35, 1244-1259.	3.5	14
12	Current trends in quantitative structure-activity relationship validation and applications on drug discovery. <i>Future Science OA</i> , 2017, 3, FSO214.	1.9	8
13	The Role of QSAR and Virtual Screening Studies in Type 2 Diabetes Drug Discovery. <i>Medicinal Chemistry</i> , 2017, 13, 706-720.	1.5	7
14	Understanding PPAR- $\gamma$ affinity and selectivity using hologram quantitative structure-activity modeling, molecular docking and GRID calculations. <i>Future Medicinal Chemistry</i> , 2016, 8, 1913-1926.	2.3	2
15	In silico studies on the interaction between bioactive ligands and ALK5, a biological target related to the cancer treatment. <i>Journal of Biomolecular Structure and Dynamics</i> , 2016, 34, 2045-2053.	3.5	7
16	Structure-Based Virtual Screening and Discovery of New PPAR $\gamma$ / $\beta$ Dual Agonist and PPAR $\gamma$ and $\beta$ Agonists. <i>PLoS ONE</i> , 2015, 10, e0118790.	2.5	21
17	Theoretical study of tautomers and photoisomers of avobenzene by DFT methods. <i>Journal of Molecular Modeling</i> , 2015, 21, 319.	1.8	20
18	Hologram quantitative structure-activity relationship and comparative molecular interaction field analysis of aminothiazole and thiazolesulfonamide as reversible LSD1 inhibitors. <i>Future Medicinal Chemistry</i> , 2015, 7, 1381-1394.	2.3	12

#	ARTICLE	IF	CITATIONS
19	Molecular Features Related to HIV Integrase Inhibition Obtained from Structure- and Ligand-Based Approaches. PLoS ONE, 2014, 9, e81301.	2.5	6
20	Hologram QSAR Studies of Antiprotozoal Activities of Sesquiterpene Lactones. Molecules, 2014, 19, 10546-10562.	3.8	15
21	Understanding electrostatic and steric requirements related to hypertensive action of AT1 antagonists using molecular modeling techniques. Journal of Molecular Modeling, 2014, 20, 2231.	1.8	2
22	Computational studies of TGF- $\beta$ RI (ALK-5) inhibitors: Analysis of the binding interactions between ligand and receptor using 2D and 3D techniques. European Journal of Pharmaceutical Sciences, 2013, 49, 542-549.	4.0	18
23	Advanced QSAR studies on PPAR $\gamma$ ligands related to metabolic diseases. Journal of the Brazilian Chemical Society, 2012, 23, 78-84.	0.6	23
24	Ligand and Structure-Based Drug Design Strategies and PPAR $\gamma$ Selectivity. Chemical Biology and Drug Design, 2012, 80, 533-544.	3.2	8
25	Role of physicochemical properties in the activation of peroxisome proliferator-activated receptor $\gamma$ . Journal of Molecular Modeling, 2011, 17, 2549-2558.	1.8	12
26	Theoretical study on the molecular and electronic properties of some substances used for diabetes mellitus treatment. Journal of Molecular Modeling, 2010, 16, 799-804.	1.8	15